MiMedx Q3 net sales up 20.7% to $81.7M, GAAP net income $8.5M, raises FY outlook

MIMEDX GROUP, INC.

2023-Q3 EPS reported $0.00 revenue$234,645,000

Q3 net sales $81.7M (+20.7% YoY); GAAP net income $8.5M vs loss $8.4M prior year.
Adjusted EBITDA $17.6M (21.6% margin) vs $2.4M; cash from ops $12.8M.
Raised FY2023 net sales growth outlook to high teens; expects H2 Adj. EBITDA margin >20%.
Repurchased $9.5M of Series B Preferred Stock from Hayfin; one-year lock-up.
Cash $81.2M, up from $66.0M at Dec 31, 2022; long-term debt $49.0M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MIMEDX GROUP, INC. reported the third quarter ended September 30, 2023 results: revenue $81.7 million, net income $8.5 million. Guidance raised.

Period: the third quarter ended September 30, 2023
Revenue: $81.7 million
Net income: $8.5 million
Guidance: raised
Result: reported results

Exact text from the filing

operating and financial results for the third quarter 2023, which ended September 30, 2023. Recent Operating and Financial Highlights: • Third quarter 2023 net sales of $81.7 million, an increase of 20.7% over third quarter 2022. • GAAP net income of $8.5 million for third quarter 2023. • Adjusted EBITDA 1 of $17.6 million for third quarter 2023, representing

View on SEC.gov

Browse all earnings releases →

MIMEDX GROUP, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-266161

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.